Aspirin resistance: Does it exist?

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 2, 2007, Pages 210-214

  Rao, Gundu H R ^a   Michiels, Jan Jaques ^b,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c Goodheart Institute   (Netherlands)

Author keywords

Aggregometry; Arachidonic acid; Aspirin; Aspirin resistance; COX 1; Laboratory testing; Malondialdehyde

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 1 INHIBITOR; DIPYRIDAMOLE; INDOMETACIN; MALONALDEHYDE; SALICYLATE SODIUM; SULFINPYRAZONE;

ANALGESIA; ARTICLE; DOSE RESPONSE; ENZYME INHIBITION; HUMAN; LABORATORY DIAGNOSIS; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ARACHIDONIC ACID; ASPIRIN; CYCLOOXYGENASE 1; DIAGNOSTIC ERRORS; DRUG RESISTANCE; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES;

EID: 33947223747     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-969036     Document Type: Article

References (21)

1. Rao GHR. Aspirin resistance: a fact or a myth? Exp Clin Cardiol 2005;10:17-20
2. Rao GHR. Aspirin resistance: need for a specific and rapid assay. World Heart J 2006;1:63-78
3. Pollack A. New York Times 2004.
4. Roth JG, Caverley DC. Aspirin, platelets and thrombosis: theory and practice. Blood 1994;83:885-898
5. Roth JG, Stanford N, Majerus PW. Acetylation of prostaglandin synthetase by aspirin. Proc Natl Acad Sci USA 1975;72:3073-3076
6. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. J Clin Invest 1975;56:624-632
7. Smith JB, Ingerman CM, Silver MJ. Malodialdehyde formation as an indicator of prostaglandin production by human platelets. J Lab Clin Med 1976;13:167-172
8. Michiels JJ, Abels J, Steketee J, van Vliet HHDM, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 1985;102:466-471
9. Michiels JJ, Zijlstra FJ. Prostaglandin cyclooxygenase products but not thromboxane A2 are involved in the pathogenesis of erythromelalgia in thrombocythemia. Mediators Inflamm 1993;2:385-389
10. Van Genderen PJJ, Lucas IS, van Strik R, et al. Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemost 1996;76:333-338
11. Van Genderen PJJ, Prins F, Michiels JJ, Schrör K. Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Br J Haematol 1999;104:438-441
12. Michiels JJ, Berneman Z, Schroyens W, et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera. A distinct aspirin-responsive and coumadin resistant arterial thrombophilia. Platelets 2006;17:528-544
13. Van Genderen PJJ, Mulder PGH, Waleboer M, van de Moesdijk D, Michiels JJ. Prevention and treatment of thrombotic complications in essential thrombocythemia: efficacy and safety of aspirin. Br J Haematol 1997;97:179-184
14. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera: results of the ECLAP trial. N Engl J Med 2004;350:114-124
15. Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, van Vliet HHDM. Platelet-mediated thrombotic complications in patients with ET: reversal by aspirin, platelet reduction but not by coumadin. Blood Cells Mol Dis 2006;36:199-205
16. Rao GHR, White JG. Epinephrine potentiation of arachidonate induced aggregation of cyclooxygenase deficient platelets. Am J Hematol 1981;11:355-366
17. Swier P, Mohammad SF, Olsen DB, Kolff WJ. A comparison of the antiplatelet effect of aspirin on human and bovine platelets. ASAIO Trans 1989;35:205-208
18. Rao GHR, Ericson DG, Weiss DJ, Park PG, White JG. Influence of aspirin and carbacyclin on bovine platelet function. ASAIO J 1992;38:830-834
19. Rao GHR, Johnson JG, White JG. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis 1983;3:384-388
20. Rao GHR, Johnson GJ, White JG. Influence of epinephrine on the aggregation response of aspirin-treated platelets. Prost Med 1980;5:45-48
21. Rao GHR, Escolar G, White JG. Epinephrine reverses the inhibitory influence of aspirin on platelet-vessel wall interactions. Thromb Res 1986;44:65-74